Search Results

AudioCure Pharma GmbH announced that it has been awarded for its innovative compound AC102 by the Hearing Technology Innovator Awards™, honoring technological innovation and breakthroughs in the hearing industry.

FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, and European partner, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.

Renexxion Ireland Limited announced that its European Partner, Dr. Falk Pharma GmbH, has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease as the second indication in their licensed territories.

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

FundaMental Pharma GmbH announced the appointment of Dr. Lorenz Mayr to its Board of Directors.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models.